Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm IncfiledCriticalBiomarin Pharm Inc
Publication of AR118157A2publicationCriticalpatent/AR118157A2/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Se describen composiciones que comprenden enzimas lisosomales sulfatasa activas y altamente fosforiladas, sus composiciones farmacéuticas, métodos para producir y purificar dichas enzimas lisosomales sulfatasa y su empleo en el diagnóstico, la profilaxis y el tratamiento de enfermedades y afecciones, incluso particularmente las enfermedades pro almacenamiento lisosomal que son provocadas -o que se asocian con- la deficiencia de dicha enzima lisosomal sulfatasa.Compositions comprising active and highly phosphorylated lysosomal sulfatase enzymes, their pharmaceutical compositions, methods for producing and purifying said lysosomal sulfatase enzymes and their use in the diagnosis, prophylaxis and treatment of diseases and conditions, including particularly lysosomal storage diseases, are described. that are caused by - or associated with the deficiency of said lysosomal enzyme sulfatase.
ARP200100475A2008-01-182020-02-20
A RECOMBINANT HUMAN N-ACETYLGALACTOSAMINE-6-SULFATASE (GALNS) ENZYME, COMPOSITION AND ITS USES
AR118157A2
(en)
Pharmaceutical composition comprising mycophenolate sodium and its use for the treatment and / or prevention of autoimmune diseases such as rejection of allografts or xenografts of organs, cells or tissues and as an anti-inflammatory.